Abstract 439P
Background
Ewing’s sarcoma and osteosarcoma have high incidence in teenage and young adults (TYA) with age range(15-29 years). This study investigated the epidemiology of cancers among TYA population,with a special emphasis on Ewing’s sarcoma, evaluating theimpact of symptom delay and system delay variables on the patient outcomes.
Methods
This was a single-center, retrospective cross-sectional study conducted between June 2015 and March 2020 on TYA patients with a confirmed diagnosis of cancer. TYA patients registered with Ewing’s sarcoma were selected for the study using a non-probability sampling technique. The symptom delay was defined as >1 month duration from the first symptom to the consultation by primary care physician (PCP). The system delay was defined as >1 month duration from initial consultation by PCP to referring the patient to a dedicated cancer center.
Results
Our study gives a comprehensive overview of cancer epidemiology among TYA patients. Our observation is that 7.35% (450/6120) of our cancer patients are TYAs. Ewing’s sarcoma was found in 8.88% (40/450) of all the TYA cancer patients.Symptom delay was noted among 65.0% of patients and system delay occurred among 57.5% of patients. We observed that symptom delay and system delay at presentation had a significant impact on the patient outcome in terms of increased metastasis and reduced progression free survival. Patients with large tumor volume (>100 cc) had poor Progression Free Survival (PFS), showing a strong negative correlation between tumor volume and PFS. Mean five-year PFS for patients with no detectable metastatic disease at diagnosis was significantly better than for those with metastases (59m vs. 19m, respectively; P<.001). Table: 439P
Correlation of PFS with clinical variables
Parameter | Variable | n | PFS (months) Mean ±SD | p-value | ||
Localized Disease | No | 15 | 18.93±8.74 | p<0.001 | ||
Yes | 25 | 59.28±16.09 | ||||
Symptom Delay in Survived | No | 14 | 69.07±10.12 | p<0.001 | ||
Yes | 16 | 40.69±15.19 | ||||
System Delay in Survived | No | 16 | 66.94±12.20 | p<0.001 | ||
Yes | 14 | 39.07±14.62 |
Conclusions
Ewing’s sarcoma should be considered the prototype of a TYA cancer. Efforts in improving access to healthcare facilities, education of primary healthcare physicians, pediatricians and orthopedic surgeons is of paramount importance to facilitate an early diagnosis and establish care pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
429P - Cancer and COVID-19 in India: Assessing the impact in a nationwide survey
Presenter: Bharti Devnani
Session: Poster viewing 06
430P - Single-cell spatial architecture of tumour microenvironment in patients with in-transit melanoma (ITM)
Presenter: Camelia Quek
Session: Poster viewing 06
431P - Alveolar soft part sarcomas: A tertiary care Indian centre experience
Presenter: Jyoti Bajpai
Session: Poster viewing 06
432P - Representation of countries and gender in abstracts at the 2022 American Society of Clinical Oncology Annual Scientific Meeting (ASCO ASM)
Presenter: Laure-Anne Teuwen
Session: Poster viewing 06
433P - Variations in radiation oncology treatment access in Asia and its implications on cancer care
Presenter: Abhishek Krishna
Session: Poster viewing 06
434P - Outcome of high grade glioma patients: A single institution experience
Presenter: Adeeba Zaki
Session: Poster viewing 06
435P - The pattern of presentation of cancer in young adults from a tertiary care centre: A cause for concern
Presenter: Deepa Joseph
Session: Poster viewing 06
436P - Oncologic outcomes in patients with extraskeletal Ewing’s sarcoma (EES): A tertiary care centre experience
Presenter: Ashish Gulia
Session: Poster viewing 06
437P - The prevalence of burnout among medical oncology fellows-in-training in the Philippines: A cross-sectional study
Presenter: Daphne Lee
Session: Poster viewing 06
438P - Estimating scenarios for survival time in patients with metastatic melanoma receiving immunotherapy or targeted therapy
Presenter: Megan Smith-Uffen
Session: Poster viewing 06